Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03334630 · ClinicalTrials.gov registry record · NA
DiamondTemp™ Ablation System for the Treatment of Paroxysmal Atrial Fibrillation
A NA study, sponsored by Medtronic Cardiac Ablation Solutions.
- Completed
- Registry status
- NA
- Development phase
- 482
- Enrollment target
NCT03334630 is a NA study that has completed, run by Medtronic Cardiac Ablation Solutions. The registered enrollment target is 482 participants.
The verdict
NCT03334630, a NA study, has completed, sponsored by Medtronic Cardiac Ablation Solutions.
- COMPLETED
- Registry status
- NA
- Development phase
- 482 participants
- Enrollment target
Study Summary
The purpose of the DIAMOND-AF study is to establish the safety and effectiveness of the DiamondTemp System for the treatment of drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation in patients.
Interventions
- DEVICE DiamondTemp Ablation catheter
- DEVICE TactiCath Quartz Ablation catheter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 482 participants |
| Start Date | 2017-11-06 |
| Est. Completion | 2019-12-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03334630
The ClinicalTrials.gov registry entry for NCT03334630 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 482 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Ablation Solutions, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DiamondTemp Ablation catheter is the first listed.
NCT03334630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03334630 about?
NCT03334630 is a clinical study titled "DiamondTemp™ Ablation System for the Treatment of Paroxysmal Atrial Fibrillation". The purpose of the DIAMOND-AF study is to establish the safety and effectiveness of the DiamondTemp System for the treatment of drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation in patients.
What is the current status of trial NCT03334630?
This trial is currently completed. It is a NA study. The enrollment target is 482 participants. The study started on 2017-11-06. Estimated completion is 2019-12-03.
What interventions are being tested in trial NCT03334630?
The interventions under investigation include: DiamondTemp Ablation catheter (DEVICE), TactiCath Quartz Ablation catheter (DEVICE).
Who is sponsoring clinical trial NCT03334630?
This trial is sponsored by Medtronic Cardiac Ablation Solutions, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.